- Home
- SLXN vs FGI Comparison
SLXN vs FGI Comparison
Compare SLXN & FGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- FGI
- Stock Information
- Founded
- SLXN 2008
- FGI 1987
- Country
- SLXN Israel
- FGI United States
- Employees
- SLXN N/A
- FGI N/A
- Industry
- SLXN
- FGI Industrial Specialties
- Sector
- SLXN
- FGI Industrials
- Exchange
- SLXN NYSE
- FGI Nasdaq
- Market Cap
- SLXN 7.3M
- FGI 5.5M
- IPO Year
- SLXN N/A
- FGI 2022
- Fundamental
- Price
- SLXN $0.80
- FGI $0.65
- Analyst Decision
- SLXN Strong Buy
- FGI
- Analyst Count
- SLXN 1
- FGI 0
- Target Price
- SLXN $5.00
- FGI N/A
- AVG Volume (30 Days)
- SLXN 714.1K
- FGI 167.0K
- Earning Date
- SLXN 08-21-2025
- FGI 08-06-2025
- Dividend Yield
- SLXN N/A
- FGI N/A
- EPS Growth
- SLXN N/A
- FGI N/A
- EPS
- SLXN N/A
- FGI N/A
- Revenue
- SLXN N/A
- FGI $134,277,102.00
- Revenue This Year
- SLXN N/A
- FGI $7.72
- Revenue Next Year
- SLXN N/A
- FGI $6.94
- P/E Ratio
- SLXN N/A
- FGI N/A
- Revenue Growth
- SLXN N/A
- FGI 11.13
- 52 Week Low
- SLXN $0.58
- FGI $0.46
- 52 Week High
- SLXN $41.85
- FGI $1.20
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- FGI 48.82
- Support Level
- SLXN N/A
- FGI $0.64
- Resistance Level
- SLXN N/A
- FGI $0.67
- Average True Range (ATR)
- SLXN 0.00
- FGI 0.09
- MACD
- SLXN 0.00
- FGI 0.00
- Stochastic Oscillator
- SLXN 0.00
- FGI 29.03
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.